Halozyme Therapeutics (NASDAQ:HALO) Hits New 52-Week High – Still a Buy?

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s share price hit a new 52-week high during trading on Wednesday . The stock traded as high as $104.78 and last traded at $102.62, with a volume of 2845965 shares. The stock had previously closed at $102.62.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on HALO shares. TD Cowen raised their price objective on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the company from $83.00 to $110.00 in a research note on Friday, August 7th. HC Wainwright raised their target price on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Finally, Citizens Jmp lifted their price target on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $91.20.

Halozyme Therapeutics Trading Down 1.1%

The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The stock has a market cap of $11.43 billion, a price-to-earnings ratio of 30.05, a P/E/G ratio of 0.41 and a beta of 0.85. The company has a fifty day simple moving average of $79.11 and a 200-day simple moving average of $72.36.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same period last year, the company posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $51,886,572.40. The trade was a 2.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director owned 14,462 shares of the company’s stock, valued at $1,084,650. The trade was a 33.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 44,103 shares of company stock worth $3,142,896. Corporate insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Measured Wealth Private Client Group LLC lifted its position in shares of Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 124 shares in the last quarter. Abel Hall LLC increased its stake in Halozyme Therapeutics by 4.2% in the 4th quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock valued at $216,000 after buying an additional 129 shares during the period. StoneX Group Inc. increased its stake in Halozyme Therapeutics by 3.8% in the 4th quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 132 shares during the period. Moran Wealth Management LLC lifted its position in Halozyme Therapeutics by 0.4% in the 4th quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock worth $2,396,000 after buying an additional 151 shares in the last quarter. Finally, Twin Capital Management Inc. lifted its position in Halozyme Therapeutics by 1.4% in the 1st quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock worth $738,000 after buying an additional 161 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.